Publication Cover
Xenobiotica
the fate of foreign compounds in biological systems
Volume 46, 2016 - Issue 11
1,102
Views
25
CrossRef citations to date
0
Altmetric
Clinical Pharmacokinetics and Metabolism

Disposition and metabolism of [14C] Sacubitril/Valsartan (formerly LCZ696) an angiotensin receptor neprilysin inhibitor, in healthy subjects

, , , , , , , , , , & show all
Pages 986-1000 | Received 07 Nov 2014, Accepted 30 Jan 2015, Published online: 02 Mar 2016

References

  • Criscione L, deGasparo M, Bühlmayer P, et al. (1993). Pharmacological profile of valsartan: a potent, orally active, nonpeptide antagonist of the angiotensin II AT1-receptor subtype. Br J Pharmacol 110:761–71
  • Dhuria S, Einolf H, Mangold J, et al. (2008). Time-dependent inhibition and induction of human cytochrome P4503A4/5 by an oral IAP antagonist, LCL161, in vitro and in vivo in healthy subjects. J Clin Pharmacol 53:642–53
  • Gu J, Noe A, Chandra P, et al. (2010). Pharmacokinetics and pharmacodynamics of LCZ696, a novel dual-acting angiotensin receptor-neprilysin inhibitor (ARNi). J Clin Pharmacol 50:401–4
  • He H, Tran P, Yin H, et al. (2009). Absorption, metabolism, and excretion of [14C]vildagliptin, a novel dipeptidyl peptidase 4 inhibitor, in humans. Drug Metab Dispos 37:536–44
  • Nodaa K, Nakayamaa K, Moddermanb J. (1996). Fate of erythritol after single oral administration to rats and dogs. Regul Toxicol Pharmacol 24:S206–13
  • Lee CY, Burnett JC Jr. (2007). Natriuretic peptides and therapeutic applications. Heart Fail Rev 12:131–42
  • McKeage MJ, Fong PC, Hong X, et al. (2012). Mass balance, excretion and metabolism of [14C] ASA404 in cancer patients in a phase I trial. Cancer Chemother Pharmacol 69:1145–54
  • Rubattu S, Sciarretta S, Valenti V, et al. (2008). Natriuretic peptides: an update on bioactivity, potential therapeutic use, and implication in cardiovascular diseases. Am J Hypertens 21:733–41
  • Taavitsainen P, Kiukaanniemi K, Pelkonen O. (2000). In vitro inhibition screening of human hepatic P450 enzymes by five angiotensin-II receptor antagonists. Eur J Clin Pharmacol 56:135–40
  • Valentin J. (2007). The 2007 recommendations of the international commission on radiological protection. ICRP publication 103. Ann ICRP 37(2--4):1–332
  • Vardeny O, Tacheny T, Solomon SD. (2013). First-in-class angiotensin receptor neprilysin inhibitor in heart failure. Clin Pharmacol Ther 94:445–8
  • Volpe M, Rubattu S, Burnett J Jr. (2014). Natriuretic peptides in cardiovascular diseases: current use and perspectives. Eur Heart J 35:419–25
  • Waldmeier F, Flesch G, Müller P, et al. (1997). Pharmacokinetics, disposition and biotransformation of [14C]-radiolabelled valsartan in healthy male volunteers after a single oral dose. Xenobiotica 27:59–71

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.